FDA — authorised 3 July 2008
- Marketing authorisation holder: BAYER HLTHCARE
- Status: approved
FDA authorised Eovist on 3 July 2008
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 3 July 2008.
BAYER HLTHCARE holds the US marketing authorisation.